Application No.: 10/665,888 Docket No.: 466992000900

Potential Claims

1. (Currently amended) A method for assaying for potassium ions in a sample, which method comprises:

- a) contacting the sample with a potassium dependent urea amidolyase (UAL), wherein the UAL eonsumes catalyzes the carboxylation of urea and forms P_i and ADP; and
- b) assessing the consumption concentration of urea and/or the formation of P_i in step a) to determine assay for the presence or amount of potassium ions in the sample.
 - 2. (original) The method of claim 1, wherein the sample is a biological sample.
 - 3. (original) The method of claim 2, wherein the biological sample is a blood sample.
- 4. (original) The method of claim 3, wherein the blood sample is a plasma, serum, red blood cell, or whole blood sample.
- 5. (original) The method of claim 1, wherein the UAL catalyzes the formation of Pi in the following net reaction:

Urea + ATP + HCO₃ + 4H₂O
$$\xrightarrow{\text{UAL}}$$
 ADP + P_i + 2HCO₃ + 2NH₄ + OH.

- 6. (original) The method of claim 1, wherein the amount of P_i formed correlates with the amount of potassium ions in the sample.
- 7. (original) The method of claim 1, which is used in a prognosis or diagnosis of a disease or disorder.
- 8. (original) A method for assaying for potassium ions in a sample, which method comprises:

Application No.: 10/665,888 Docket No.: 466992000900

a) contacting the sample with a first composition comprising a potassium-dependent urea amidolyase;

- b) contacting the sample with a second composition comprising urea; and
- c) assessing the production of P_i to determine the presence or amount of potassium ions in the sample.
 - 9. (original) The method of claim 8, wherein the sample is a biological sample.
 - 10. (original) The method of claim 9, wherein the biological sample is a blood sample.
- 11. (original) The method of claim 10, wherein the blood sample is a plasma, serum, red blood cell, or whole blood sample.
- 12. (original) The method of claim 8, wherein the first composition further comprises glycogen, phosphorylase a, oxidized β-nictinamide adenine dinucleotide (NAD), phosphoglucomutase, glucose-6-phosphate dehydrogenase (G-6-PDH), 2-(4-iodophenyl)-3-(4-nitrophenyl)-5(2,4-disulfophenyl)-2H-tetrazolium (WST-1), and 1-methoxy-5-methyl-phenazinium methyl sulfate (PMS), and the second composition further comprises adenine triphosphate (ATP) and MgCl₂.
- 13. (original) The method of claim 12, wherein the second composition further comprises a protein.
- 14. (original) The method of claim 13, wherein the protein is bovine serum albumin (BSA).
- 15. (original) The method of claim 12, wherein the second composition further comprises a buffer.
 - 16. (original) The method of claim 15, wherein the buffer is NaHCO₃.

Application No.: 10/665,888 Docket No.: 466992000900

17. (currently amended) The method of claim 12 27, wherein the detectable product is formazan.

18. (original) The method of claim 8, which is used in a prognosis or diagnosis of a disease or disorder.

19-26. (Canceled)

27. (new) The method of claim 12, wherein the assessment of production of P_i comprises the detection of a detectable product.